Skip to main content
SpringerLink
Log in

Clinical Pharmacology and Therapeutic Potential of Monoclonal Antibody Treatment in Rheumatoid Arthritis

  • Review Article
  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Many monoclonal antibodies (mAb) have been tested in rheumatoid arthritis (RA). Murine antibodies were antigenic and caused human antimouse responses in the recipients. As a result, re-treatments were less effective and were associated with an increased risk of anaphylaxis. Advances in biotechnology have allowed us to develop chimaeric and humanised mAb that are less antigenic than their murine equivalents.

The specificity of mAb allows targeting of particular inflammatory mediators that are thought to be pathogenic in RA. In clinical trials, anti-cytokine antibodies such as anti-tumour necrosis factor-a mAb reduced inflammation rapidly and produced marked symptomatic improvement. The clinical improvement was related to the dosage and plasma concentration of the antibody.

When depleting anti-lymphocyte mAb were used in RA, they produced variable clinical responses. One of the explanations for this is the poor penetration of anti-lymphocyte antibodies into the synovial joint. Therefore, depletion of lymphocytes was much greater in the blood than in the synovial joints. Consequently, this approach has been abandoned and, recently, nondepleting anti-CD4 mAb have been tested in RA. When sufficient dosages were given, they produced clinical improvement, but more studies are required to assess whether they can lead to long term disease suppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7

    Article  PubMed  Google Scholar 

  2. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992–9

    Article  PubMed  CAS  Google Scholar 

  3. Kavanaugh AF, Schulze-Koops H, Davis LS, et al. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule-1 monoclonal antibody. Arthritis Rheum 1997; 40: 849–53

    Article  PubMed  CAS  Google Scholar 

  4. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293–9

    Article  PubMed  CAS  Google Scholar 

  5. Marks C, Marks JD. Phage libraries — a new route to clinically useful antibodies. N Engl J Med 1996; 335: 730–3

    Article  PubMed  CAS  Google Scholar 

  6. Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; I: 1108–11

    Article  Google Scholar 

  7. Pincus T, Marcum SB, Callahan LF. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885–94

    PubMed  CAS  Google Scholar 

  8. Isler P, Vey E, Zhang J, et al. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993; 4: 15–23

    PubMed  CAS  Google Scholar 

  9. Paulnock DM. Macrophage activation by T cells. Curr Opin Immunol 1992; 4: 344–9

    Article  PubMed  CAS  Google Scholar 

  10. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754–9

    Article  PubMed  CAS  Google Scholar 

  11. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 729–35

    Article  PubMed  CAS  Google Scholar 

  12. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990; 33: 768–73

    Article  PubMed  CAS  Google Scholar 

  13. Brennan FM, Maini RN, Feldmann M. TNF alpha — a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293–8

    Article  PubMed  CAS  Google Scholar 

  14. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31

    PubMed  CAS  Google Scholar 

  15. Chu CQ, Field M, Allard S, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31: 653–61

    Article  PubMed  CAS  Google Scholar 

  16. Elliott MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  17. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42

    Article  PubMed  CAS  Google Scholar 

  18. Choy EHS, Kassimos D, Kingsley GH, et al. The effect of an engineered human anti-tumour necrosis factor alpha (TNFα) antibody (Ab) on interleukin-6 (IL-6) and bone markers in rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1995; 38 Suppl.: S185

    Google Scholar 

  19. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7

    Article  PubMed  CAS  Google Scholar 

  20. Rankin ECC, Choy EHS, Sopwith M, et al. Repeated doses of 10mg/kg of an engineered human anti-TNFα antibody, CDP571, in RA patients are safe and effective [abstract]. Arthritis Rheum 1995; 38 Suppl.: S185

    Google Scholar 

  21. Rankin ECC, Ravirajan CT, Ehrenstein MR, et al. Serological effects following treatment with an engineered human anti-TNFα antibody, CDP571 in patients with rheumatoid arthritis (RA) [abstract]. Br J Rheumatol 1995; 34Suppl. 1: 101

    Google Scholar 

  22. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62

    PubMed  CAS  Google Scholar 

  23. Pitzalis C, Kingsley G, Panayi G. Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy. Ann Rheum Dis 1994; 53: 287–8

    Article  PubMed  CAS  Google Scholar 

  24. Davis LS, Kavanaugh AF, Nichols LA, et al. Alteration in circulating T cell subsets as a result of treatment of rheumatoid arthritis patients with a monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1) [abstract]. Arthritis Rheum 1992; 35: S43

    Article  Google Scholar 

  25. Quagliata F, Schenkelaars EJ, Ferrone S. Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4. Isr J Med Sci 1993; 29: 154–9

    PubMed  CAS  Google Scholar 

  26. Isaacs JD, Watts RA, Hazelman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748–52

    Article  PubMed  CAS  Google Scholar 

  27. Olsen NJ, Brooks RH, Cush JJ, et al. A double-blind, placebocontrolled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1102–8

    Article  PubMed  CAS  Google Scholar 

  28. Choy EHS, Chikanza IC, Kingsley GH, et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992; 36: 291–8

    Article  PubMed  CAS  Google Scholar 

  29. Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36: 307–18

    Article  PubMed  CAS  Google Scholar 

  30. vander Lubbe PA, Dijkmans BA, Markusse HM, et al. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097–106

    Article  PubMed  Google Scholar 

  31. Kirkham BW, Pitzalis C, Kingsley GH, et al. Monoclonal antibody treatment in rheumatoid arthritis: clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991; 30: 459–63

    Article  PubMed  CAS  Google Scholar 

  32. Kirkham BW, Thien F, Pelton BK, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992; 19: 1348–52

    PubMed  CAS  Google Scholar 

  33. Lazarovits AI, White MJ, Karsh J. CD7 T cells in rheumatoid arthritis. Arthritis Rheum 1992; 35: 615–24

    Article  PubMed  CAS  Google Scholar 

  34. Strand V, Lipsky PE, Cannon GW, CD5 Plus Rheumatoid Arthritis Investigators Group, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993; 36: 620–30

    Article  PubMed  CAS  Google Scholar 

  35. Isaacs JD, Manna VK, Rapson N, et al. Campath-1H in rheumatoid arthritis — an intravenous dose-ranging study. Br J Rheumatol 1996; 35: 231–40

    Article  PubMed  CAS  Google Scholar 

  36. Ruderman EM, Weinblatt ME, Thurmond LM, et al. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995; 38: 254–8

    Article  PubMed  CAS  Google Scholar 

  37. Poynton CH, Mort D, Maughan TS. Adverse reactions to Campath-1H monoclonal antibody [letter]. Lancet 1993; 341: 1037

    Article  PubMed  CAS  Google Scholar 

  38. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995; 38: 1187–93

    Article  PubMed  CAS  Google Scholar 

  39. Vanden Broek MF, Vande Langerijt LG, Van Bruggen MC, et al. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1992; 22: 57–61

    Article  PubMed  Google Scholar 

  40. Horneff G, Burmester GR, Emmrich F, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34: 129–40

    Article  PubMed  CAS  Google Scholar 

  41. Reiter C, Kakavand B, Rieber EP, et al. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991; 34: 525–36

    Article  PubMed  CAS  Google Scholar 

  42. Wendling D, Wijdenes J, Racadot E, et al. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991; 18: 325–7

    PubMed  CAS  Google Scholar 

  43. vander Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993; 36: 1375–9

    Article  PubMed  Google Scholar 

  44. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 1581–8

    Article  PubMed  CAS  Google Scholar 

  45. Choy EH, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996; 39: 52–6

    Article  PubMed  CAS  Google Scholar 

  46. Herzog C, Walker C, Muller W, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmunity 1989; 2: 627–42

    Article  CAS  Google Scholar 

  47. Wendling D, Racadot E, Morel-Fourrier B, et al. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody: open study of 25 patients with the B-F25 clone. Clin Rheumatol 1992; 11: 542–7

    Article  PubMed  CAS  Google Scholar 

  48. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996; 39: 1773–80

    Article  PubMed  CAS  Google Scholar 

  49. Scoazec JY, Feldmann G. Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus. Hepatology 1990; 12: 505–10

    Article  PubMed  CAS  Google Scholar 

  50. Panayi GS, Choy EHS, Connolly DJA, et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment: I. Suppression of disease activity and acute phase response [abstract]. Arthritis Rheum 1996; 39 Suppl.: S244

    Google Scholar 

  51. Levy R, Weisman M, Wiesenhutter C, et al. Results of a placebocontrolled, multicenter trial using a primatized, non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S122

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Unit, Guy’s and King’s College Hospitals, London, England

    Ernest H. S. Choy

Authors
  1. Ernest H. S. Choy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernest H. S. Choy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choy, E.H.S. Clinical Pharmacology and Therapeutic Potential of Monoclonal Antibody Treatment in Rheumatoid Arthritis. Drugs & Aging 12, 139–148 (1998). https://doi.org/10.2165/00002512-199812020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199812020-00006

Keywords

Search

Navigation